Controversies in colorectal cancer: First line treatment with epidermal growth factor inhibitors and RAS in 2014
Saved in:
| Main Author: | Gilberto de Lima Lopes Junior |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Medical and Scientific Publishers Pvt. Ltd.
2014-01-01
|
| Series: | Indian Journal of Medical and Paediatric Oncology |
| Online Access: | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2014;volume=35;issue=2;spage=140;epage=142;aulast=Junior |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of epidermal growth factor receptor gene expression level on clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients taking first-line epidermal growth factor receptor–tyrosine kinase inhibitors
by: Huang-Chih Chang, et al.
Published: (2017-03-01) -
Epidermal Growth Factor Receptor Exon 19 Deletion Subtypes Do Not Influence Survival Outcomes Following First-line Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitors in Advanced Nonsmall Cell Lung Cancer Patients
by: Yan-Jei Tang, et al.
Published: (2024-01-01) -
A novel epidermal growth factor receptor inhibitor for treating lung cancer
by: Jiansheng Gao, et al.
Published: (2017-03-01) -
Antitumor effect of a new human epidermal growth factor receptor inhibitor
by: O. I. Kit, et al.
Published: (2024-09-01) -
Comparative analysis of first-generation epidermal growth factor receptor inhibitors combined with chemotherapy versus third-generation epidermal growth factor receptor inhibitors in the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis
by: Siyan Peng, et al.
Published: (2025-08-01)